Drug Trial Radar · NCT07444541
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Aug 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Anova Innovation LimitedIndustry
- Sponsor type
- Industry
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic pancreatic cancer.
Conditions
- Pancreatic Cancer
Interventions
ANO31905Drug
ANO31905 will be administered as an IV infusion
AG [gemcitabine+nab-paclitaxel]Drug
125 mg/m\^2 of nab-paclitaxel, intravenous infusion, D1/D8/D15 per cycle; 1000 mg/m\^2 of gemcitabine, intravenous infusion, D1/D8/D15 per cycle until PD, intolerable toxicity or other discontinuation criteria specified in the protocol (whichever occurs first).
mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]Drug
Oxaliplatin, 85 mg/m\^2; irinotecan (non-liposome injection), 180 mg/m\^2; leucovorin, 400 mg/m\^2; and fluorouracil, 2400 mg/m\^2 given as a 46-hour continuous infusion, on D1/D15 per cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT) (Phase Ib).Time frame: At the end of Cycle 1 (each cycle is 28 days)
- Objective response rate (ORR) assessed by the investigator according to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST v1.1) (Phase Ⅱ)Time frame: Up to 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Site 01002
Los Angeles, California · Recruiting
Site 01009
Plantation, Florida · Recruiting
Site 01005
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.